USD
+$0.00
(+0.00%
)At Close (As of Oct 13, 2025)
$1.37B
Market Cap
-
P/E Ratio
-0.98
EPS
$18.35
52 Week High
$9.02
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $65M |
Total Revenue | $76M |
Cost Of Revenue | $11M |
Costof Goods And Services Sold | $11M |
Operating Income | -$120M |
Selling General And Administrative | $62M |
Research And Development | $135M |
Operating Expenses | $185M |
Investment Income Net | - |
Net Interest Income | $20M |
Interest Income | $20M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $11M |
Income Before Tax | -$117M |
Income Tax Expense | $6.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$123M |
Comprehensive Income Net Of Tax | - |
Ebit | -$117M |
Ebitda | -$105M |
Net Income | -$123M |
Field | Value (USD) |
---|---|
Total Assets | $463M |
Total Current Assets | $300M |
Cash And Cash Equivalents At Carrying Value | $66M |
Cash And Short Term Investments | $66M |
Inventory | - |
Current Net Receivables | $56M |
Total Non Current Assets | $163M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $4.6M |
Intangible Assets Excluding Goodwill | $4.6M |
Goodwill | $12M |
Investments | - |
Long Term Investments | $98M |
Short Term Investments | $160M |
Other Current Assets | $19M |
Other Non Current Assets | - |
Total Liabilities | $124M |
Total Current Liabilities | $88M |
Current Accounts Payable | $3.9M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.7M |
Total Non Current Liabilities | $36M |
Capital Lease Obligations | $19M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $19M |
Other Current Liabilities | $55M |
Other Non Current Liabilities | $895K |
Total Shareholder Equity | $339M |
Treasury Stock | - |
Retained Earnings | -$830B |
Common Stock | $1T |
Common Stock Shares Outstanding | $76M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$110M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $11M |
Capital Expenditures | $3.1M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $39M |
Cashflow From Financing | -$20M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$30M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$123M |
Field | Value (USD) |
---|---|
Gross Profit | $65M |
Total Revenue | $76M |
Cost Of Revenue | $11M |
Costof Goods And Services Sold | $11M |
Operating Income | -$120M |
Selling General And Administrative | $62M |
Research And Development | $135M |
Operating Expenses | $185M |
Investment Income Net | - |
Net Interest Income | $20M |
Interest Income | $20M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $11M |
Income Before Tax | -$117M |
Income Tax Expense | $6.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$123M |
Comprehensive Income Net Of Tax | - |
Ebit | -$117M |
Ebitda | -$105M |
Net Income | -$123M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Zymeworks Inc. is a Vancouver-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative biotherapeutics for cancer treatment. Its proprietary platforms enable the development of a diverse pipeline of product candidates, including a range of antibody-drug conjugates and bispecific therapeutics. With a commitment to advancing targeted therapies, Zymeworks aims to address unmet medical needs in oncology, positioning itself as a key player in the biopharmaceutical industry. The company's strategic collaborations and robust R&D capabilities further enhance its potential to deliver transformational treatments to patients.